Stocks Health care OGN
NYSE · Health careOrganon & Co. (OGN)
Organon & Co. brought in $6.1B of revenue over the twelve months to September 30, 2026, down 3.2% from a year earlier. Net income was $213M, a net margin of 3.5%. Operating cash flow minus capital spending left $538M of free cash flow in fiscal 2025. At September 30, 2026 it held $1.5B in cash against $8.6B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 30, 2026.
Key facts about Organon & Co.
- Net worth
- Organon & Co. has a market value (market cap) of $3.6B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $6.2B (-2.9% year on year), with net income of $187M. Over the 12 months to September 30, 2026: revenue $6.1B, net income $213M.
- Cash flow
- In fiscal 2025 operations brought in $700M of cash; after $162M of capital spending, free cash flow was $538M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 30, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Dividend
- Organon & Co. declared dividends of $0.34 per share in fiscal 2025, a yield of 2.45% at the current price.
What Organon & Co. does
Organon & Co. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker OGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.2B | $187M | $0.72 | $538M |
| 2024 | $6.4B | $864M | $3.33 | $764M |
| 2023 | $6.3B | $1B | $3.99 | $548M |
| 2022 | $6.2B | $917M | $3.59 | $662M |
| 2021 | $6.3B | $1.4B | $5.31 | $2B |
| 2021 | $6.5B | $2.2B | $8.52 | $2B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OGN ranks in Health care
Dividends
Organon & Co. declared $0.34 per share in fiscal 2025. At the current price that is a yield of 2.45%. It paid out $88M in cash dividends, 47% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.34 | $88M | 47% |
| 2024 | $1.12 | $297M | 34% |
| 2023 | $1.12 | $294M | 29% |
| 2022 | $1.12 | $290M | 32% |
| 2021 | $0.56 | $145M | 11% |
| 2021 | n/a | $0 | 0% |
Latest SEC filings
What Organon & Co. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026
- October 30, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 1.7% to $1.6B versus the same quarter last year; diluted EPS $0.60 versus $0.61.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 2.3% to $1.6B versus the same quarter last year; diluted EPS $0.40 versus $0.56.
- July 23, 2026
- July 17, 2026Additional proxy material DEFA14A
- July 17, 2026Other event 8-K
- June 17, 2026Merger proxy statement DEFM14A
What is OGN worth? A DCF from its reported cash flow
Insider trades
What the people running Organon & Co. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 11, 2026 | Arjona Ferreira Juan CamiloHead of R&D & CMO | Exercised options | 11,519 | - |
| August 11, 2026 | Arjona Ferreira Juan CamiloHead of R&D & CMO | Shares withheld for tax | 4,134 | $56.3K |
| August 5, 2026 | Drinane Juliana PapaHead of Mfg & Supply | Sold | 14,761 | $200.3K |
| May 6, 2026 | Holzbaur LynetteSVP and Corporate Controller | Other change | 46 | - |
| May 6, 2026 | Holzbaur LynetteSVP and Corporate Controller | Sold | 26,448 | $353.1K |
| March 31, 2026 | Morrissey Joseph T. Jr.Interim CEO | Exercised options | 7,795 | - |
| March 31, 2026 | Morrissey Joseph T. Jr.Interim CEO | Shares withheld for tax | 2,221 | $12.7K |
| March 31, 2026 | Morrissey Joseph T. Jr.Interim CEO | Exercised options | 16,789 | - |
Who owns OGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Pentwater Capital Management LP13G, passive with 1 related filers | 6.9% | August 14, 2026 |
| Vanguard Portfolio Management13G, passive | 5.77% | July 31, 2026 |
| Vanguard Capital Management13G, passive | 5.26% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 631 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 32,056,866 | +339,838 |
| Pentwater Capital Management LP | 18,100,000 | new |
| Vanguard Portfolio Management LLC | 15,132,118 | -6,713,918 |
| Vanguard Capital Management LLC | 11,909,865 | +172,847 |
| State Street Corp | 9,659,371 | -297,403 |
| Goldman Sachs Group Inc | 5,199,002 | +3,593,677 |
| UBS Group AG | 4,856,529 | +1,384,950 |
| Geode Capital Management, LLC | 4,815,610 | +56,273 |
| Man Group plc | 4,180,500 | new |
| AQR Arbitrage LLC | 3,880,354 | new |
| Private Management Group Inc | 3,742,161 | -631,947 |
| Charles Schwab Investment Management Inc | 3,457,262 | +94,913 |
| Millennium Management LLC | 3,442,430 | -3,339,105 |
| Dimensional Fund Advisors LP | 3,266,826 | +1,546 |
| First Trust Advisors LP | 3,099,481 | -127,839 |
| Capula Management Ltd | 3,049,207 | new |
| Nexpoint Asset Management, L.P. | 3,009,630 | new |
| Magnetar Financial LLC | 2,810,019 | new |
| Kahn Brothers Group Inc | 2,670,523 | -2,866,470 |
| Bank of New York Mellon Corp | 2,282,161 | +50,400 |
Insiders
10 insiders reported holding 919,988 shares in total, about $12.8M at the last price.
| Holder | Shares |
|---|---|
| Walsh Matthew MChief Financial Officer | 212,746 |
| Morrissey Joseph T. Jr.Interim CEO | 123,123 |
| Stahler Rachel AChief Information Officer | 116,105 |
| Falcione AaronChief Human Resources Officer | 101,431 |
| Weaver KirkeGen. Counsel & Corp. Secy. | 92,639 |
| Cox Carrie SmithExecutive Chair, Director | 77,86977,869 held indirectly |
| Nisita VittorioHead of Global Business Svcs | 70,619 |
| Karp DanielExecutive VP, Corp. Dev. | 69,548 |
| Arjona Ferreira Juan CamiloHead of R&D & CMO | 37,432 |
| Drinane Juliana PapaHead of Mfg & Supply | 18,475 |
Questions about OGN
What does Organon & Co. do?
Organon & Co. is a company in the Health care sector, listed on NYSE as OGN. Its shares trade on NYSE under the ticker OGN.
What is Organon & Co.'s net worth?
Organon & Co. has a market value (market cap) of $3.6B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Organon & Co. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $213M on revenue of $6.1B, a net margin of 3.5%.
How much revenue does Organon & Co. make?
Over the twelve months to September 30, 2026 Organon & Co. reported revenue of $6.1B. That is 3.2% less than a year earlier.
When did Organon & Co. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 30, 2026. It covers the period to September 30, 2026.
Does Organon & Co. pay a dividend?
Yes. Organon & Co. declared dividends of $0.34 per share in fiscal 2025, a yield of 2.45% at the current price.
Similar companies
Compare OGN with
Follow OGN
Get an email when Organon & Co. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Organon & Co. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.